Recordati Overview

  • Year Founded
  • 1926

Year Founded

  • Status
  • Public

  • Employees
  • 4,700

Employees

  • Stock Symbol
  • REC

Stock Symbol

  • Investments
  • 24

  • Share Price
  • $57.87
  • (As of Thursday Closing)

Recordati General Information

Description

Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.

Contact Information

Ownership Status
Publicly Held
Financing Status
Private Equity-Backed
Corporate Office
  • Via Matteo Civitali, 1
  • 20148 Milan
  • Italy
+39 02
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
MIL
Corporate Office
  • Via Matteo Civitali, 1
  • 20148 Milan
  • Italy
+39 02

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Recordati Stock Performance

As of 19-Nov-2026, Recordati’s stock price is $57.87. Its current market cap is $12B with 208M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$57.87 $58.04 $50.16 - $62.10 $12B 208M 446K $2.98

Recordati Financials Summary

As of 30-Sep-2026, Recordati has a trailing 12-month revenue of $3.21B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 14,404,213 14,073,863 12,267,524 12,805,873
Revenue 3,213,607 2,953,552 2,533,798 2,253,239
EBITDA 1,161,300 1,000,537 861,086 766,719
Net Income 609,326 500,411 450,703 421,159
Total Assets 6,188,915 6,169,421 5,342,770 4,651,667
Total Debt 2,497,411 2,898,356 2,585,225 1,999,558
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Recordati Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Recordati‘s full profile, request access.

Request a free trial

Recordati Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical c
Pharmaceuticals
Milan, Italy
4,700 As of 2026

Basel, Switzerland
 

Barcelona, Spain
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Recordati Competitors (66)

One of Recordati’s 66 competitors is Novartis, a Corporation company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novartis Corporation Basel, Switzerland
Grifols Corporation Barcelona, Spain
Eisai Europe Corporation Hatfield, United Kingdom
Cipla Corporation Mumbai, India
Shionogi Corporation Osaka, Japan
You’re viewing 5 of 66 competitors. Get the full list »

Recordati Patents

Recordati Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4389746-A2 P2x3 receptor antagonists Inactive 21-Dec-2022
EP-4389746-A3 P2x3 receptor antagonists Inactive 21-Dec-2022
WO-2024133200-A1 P2x3 receptor antagonists Inactive 21-Dec-2022
WO-2024133200-A4 P2x3 receptor antagonists Inactive 21-Dec-2022
EP-4316468-A1 Innovative complexation of lipido-sterolic serenoa extract with tadalafil Active 03-Aug-2022 A61K9/143
To view Recordati’s complete patent history, request access »

Recordati Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Recordati Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Recordati‘s full profile, request access.

Request a free trial

Recordati Investments & Acquisitions (24)

Recordati’s most recent deal was a Merger/Acquisition with EUSA Academic Internship Experts for . The deal was made on 30-Apr-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
EUSA Academic Internship Experts 30-Apr-2026 Merger/Acquisition Educational and Training Services (B2C)
STRM.BIO 07-Jan-2026 Seed Round Drug Discovery
Sanofi (Global Rights to Enjaymo) 29-Nov-2024 Buyout/LBO Buildings and Property
EUSA Pharma (UK) 16-Mar-2022 Merger/Acquisition Pharmaceuticals
Novartis (Signifor,Signifor LAR and Osilodrostat) 23-Oct-2019 Corporate Asset Purchase Buildings and Property
You’re viewing 5 of 24 investments and acquisitions. Get the full list »

Recordati ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

23.98 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Recordati’s complete esg history, request access »

Recordati Exits (1)

Recordati’s most recent exit was on 01-Jan-1986 from Technogenetics. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Technogenetics 01-Jan-1986 Completed
To view Recordati’s complete exits history, request access »

Recordati Affiliates

Subsidiaries (8)

Name Industry Location Year Founded
EUSA Pharma (UK) Hemel Hempstead, United Kingdom 2006
Recordati Polska Warsaw, Poland 2000
Natural Point Milan, Italy 1993
Recordati Rare Diseases Puteaux, France 1990
Orphan Europe Puteaux, France 1990
You’re viewing 5 of 8 affiliates. Get the full list.  »

Recordati FAQs

  • When was Recordati founded?

    Recordati was founded in 1926.

  • Where is Recordati headquartered?

    Recordati is headquartered in Milan, Italy.

  • What is the size of Recordati?

    Recordati has 4,700 total employees.

  • What industry is Recordati in?

    Recordati’s primary industry is Pharmaceuticals.

  • Is Recordati a private or public company?

    Recordati is a Public company.

  • What is Recordati’s stock symbol?

    The ticker symbol for Recordati is REC.

  • What is the current stock price of Recordati?

    As of 19-Nov-2026 the stock price of Recordati is $57.87.

  • What is the current market cap of Recordati?

    The current market capitalization of Recordati is $12B.

  • What is Recordati’s current revenue?

    The trailing twelve month revenue for Recordati is $3.21B.

  • Who are Recordati’s competitors?

    Novartis, Grifols, Eisai Europe, Cipla, and Shionogi are some of the 66 competitors of Recordati.

  • What is Recordati’s annual earnings per share (EPS)?

    Recordati’s EPS for 12 months was $2.98.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process